| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8457604 | Nuclear Medicine and Biology | 2018 | 7 Pages |
Abstract
The theranostic, heterobivalent, agents described herein perform comparably with other mono- and multivalent conjugates we have reported and offer the potential of improved sensitivity for detecting prostate cancer cells that might exhibit differing profiles of receptor expression on tumor cells in human patients.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
![Matched-pair, 86Y/90Y-labeled, bivalent RGD/bombesin antagonist, [RGD-Glu-[DO3A]-6-Ahx-RM2], as a potential theranostic agent for prostate cancer](/preview/png/8457604.png "First Page Preview: Matched-pair, 86Y/90Y-labeled, bivalent RGD/bombesin antagonist, [RGD-Glu-[DO3A]-6-Ahx-RM2], as a potential theranostic agent for prostate cancer")
Authors
Nilantha Bandara, Tamila J. Stott Reynolds, Rebecca Schehr, Rajendra P. Bandari, Philipp J. Diebolder, Stephanie Krieger, Jingli Xu, Yubin Miao, Buck E. Rogers, Charles J. Smith,